title: Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia.
authors.forename: Francesco
authors.initials: F
authors.lastname: Zaja
authors.forename: Nicola
authors.initials: N
authors.lastname: Vianelli
authors.forename: Marta
authors.initials: M
authors.lastname: Battista
authors.forename: Alessandra
authors.initials: A
authors.lastname: Sperotto
authors.forename: Francesca
authors.initials: F
authors.lastname: Patriarca
authors.forename: Valentina
authors.initials: V
authors.lastname: Tomadini
authors.forename: Carla
authors.initials: C
authors.lastname: Filì
authors.forename: Monica
authors.initials: M
authors.lastname: Tani
authors.forename: Michele
authors.initials: M
authors.lastname: Baccarani
authors.forename: Renato
authors.initials: R
authors.lastname: Fanin
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D006801:Humans; D008875:Middle Aged; D010976:Platelet Count; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy*; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab